A5102747593- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Pleural and Pulmonary Diseases
- FOXO transcription factor regulation
- Cancer, Stress, Anesthesia, and Immune Response
- Mathematical Biology Tumor Growth
- Pituitary Gland Disorders and Treatments
- Myasthenia Gravis and Thymoma
- Medical Imaging and Pathology Studies
- Histone Deacetylase Inhibitors Research
- Occupational and environmental lung diseases
- Metabolism, Diabetes, and Cancer
- Cytomegalovirus and herpesvirus research
- Neuroendocrine Tumor Research Advances
- Pancreatic function and diabetes
- Vascular Malformations Diagnosis and Treatment
- Intracranial Aneurysms: Treatment and Complications
- Cerebrovascular and Carotid Artery Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Chromatin Remodeling and Cancer
- Management of metastatic bone disease
Vanderbilt University Medical Center
2014-2022
Vanderbilt-Ingram Cancer Center
2016-2022
Epiphany Biosciences (United States)
2022
Cancer Research UK
2021
Cancer Research UK Clinical Trials Unit
2021
University of Glasgow
2021
Vanderbilt University
2013-2021
Roswell Park Comprehensive Cancer Center
2020
Neurological Surgery
2015
Cleveland Clinic
2015
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. involvement an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, neuroradiologists, is a key factor in the appropriate cancers. Integrated histopathologic molecular characterization tumors such as gliomas should be standard practice. This article...
Metabolic complications such as obesity, hyperglycemia, and type 2 diabetes are associated with poor outcomes in patients glioblastoma. To control peritumoral edema, use of chronic high-dose steroids glioblastoma is common, which can result de novo diabetic symptoms. These metabolic may affect tumors via profound mechanisms, including activation insulin receptor (InsR) the related insulin-like growth factor 1 (IGF1R) malignant cells. In present study, we assessed expression InsR surgical...
IntroductionMalignant pleural mesothelioma (MPM) is difficult to diagnose. An accurate blood biomarker could prompt specialist referral or be deployed in future screening. In earlier retrospective studies, SOMAscan proteomics (Somalogic, Boulder, CO) and fibulin-3 seemed highly accurate, but has not been validated prospectively subsequent data have contradictory.MethodsA multicenter prospective observational study was performed 22 centers, generating a large intention-to-diagnose cohort....
Abstract Background We examined the effect of dexamethasone prescribed in initial 3 postoperative weeks on survival, steroid dependency, and infection glioblastoma patients. Methods In this single-center retrospective cohort analysis, we electronically retrieved inpatient administration outpatient prescriptions laboratory values from medical record 360 correlated total day (POD) 0 to 21 with prescription POD30 POD90, diagnosis an by POD90. These analyses were adjusted for age, Karnofsky...
Prolonged treatment with adjuvant valganciclovir has been shown in one retrospective study to exert a significant effect on overall survival (OS) newly diagnosed patients glioblastoma multiforme (GBM). However, studies evaluating the effectiveness of recurrent GBM have not performed. We evaluated setting combination bevacizumab therapy. A analysis was performed treated for off-label and at Vanderbilt University. identified 13 who received plus some point during their treatment, 8 whom were...
Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system. Myelosuppression is dose-limiting toxic effect agent temozolomide; reversible hematologic toxicity consisting mainly thrombocytopenia reported occur 7% with concomitant radiotherapy and temozolomide 14% adjuvant temozolomide.1 However, incidence secondary nonreversible disorders, such as myelodysplastic syndrome, rare complication...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...
Isocitrate dehydrogenase (IDH) mutations in low-grade gliomas (LGG) result improved survival and DNA hypermethylation compared with IDH wild-type LGGs. IDH-mutant LGGs become hypomethylated during progression. It is uncertain whether methylation changes occur GBM progression the methylome can be reprogrammed. This phase I study evaluated safety, tolerability, efficacy, after l-methylfolate (LMF) treatment, combination temozolomide bevacizumab patients recurrent high-grade glioma. Fourteen...
Abstract Background Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is mitochondrial enzyme involved in the mechanism resistance to TMZ. In prior retrospective trial, CcO activity GBMs inversely correlated clinical outcome. The current Cyto-C study was designed prospectively evaluate validate prognostic value tumor patients newly diagnosed...